Beta-Blocker Therapy in Severe Traumatic Brain Injury: A Prospective Randomized Controlled Trial

Hosseinali Khalili, Rebecka Ahl, Shahram Paydar, Gabriel Sjolin, Yang Cao, Hossein Abdolrahimzadeh Fard, Amin Niakan, Kamil Hanna, Bellal Joseph, Shahin Mohseni

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Observational studies have demonstrated improved outcomes in TBI patients receiving in-hospital beta-blockers. The aim of this study is to conduct a randomized controlled trial examining the effect of beta-blockers on outcomes in TBI patients. Methods: Adult patients with severe TBI (intracranial AIS ≥ 3) were included in the study. Hemodynamically stable patients at 24 h after injury were randomized to receive either 20 mg propranolol orally every 12 h up to 10 days or until discharge (BB+) or no propranolol (BB−). Outcomes of interest were in-hospital mortality and Glasgow Outcome Scale-Extended (GOS-E) score on discharge and at 6-month follow-up. Subgroup analysis including only isolated severe TBI (intracranial AIS ≥ 3 with extracranial AIS ≤ 2) was carried out. Poisson regression models were used. Results: Two hundred nineteen randomized patients of whom 45% received BB were analyzed. There were no significant demographic or clinical differences between BB+ and BB cohorts. No significant difference in in-hospital mortality (adj. IRR 0.6 [95% CI 0.3–1.4], p = 0.2) or long-term functional outcome was measured between the cohorts (p = 0.3). One hundred fifty-four patients suffered isolated severe TBI of whom 44% received BB. The BB+ group had significantly lower mortality relative to the BB group (18.6% vs. 4.4%, p = 0.012). On regression analysis, propranolol had a significant protective effect on in-hospital mortality (adj. IRR 0.32, p = 0.04) and functional outcome at 6-month follow-up (GOS-E ≥ 5 adj. IRR 1.2, p = 0.02). Conclusion: Propranolol decreases in-hospital mortality and improves long-term functional outcome in isolated severe TBI. This randomized trial speaks in favor of routine administration of beta-blocker therapy as part of a standardized neurointensive care protocol. Level of evidence: Level II; therapeutic. Study type: Therapeutic study.

Original languageEnglish (US)
Pages (from-to)1844-1853
Number of pages10
JournalWorld journal of surgery
Volume44
Issue number6
DOIs
StatePublished - Jun 1 2020

ASJC Scopus subject areas

  • Surgery

Fingerprint Dive into the research topics of 'Beta-Blocker Therapy in Severe Traumatic Brain Injury: A Prospective Randomized Controlled Trial'. Together they form a unique fingerprint.

Cite this